What’s up with PJT’s stock price?
Since the market downfall, PJT’s share price has remained relatively flat. All other public EB’s have nosedived.
Trending Content - Investment Banking Forum
| +167 | Worlds Worst MDs Competition (2026 Edition) | 31 | 10h |
| +164 | Who Killed Wall Street | 48 | 2h |
| +163 | As Lehman people reconvene at UBS, Barclays needs to hire (2023) | 23 | 2d |
| +106 | Lindsay Clancy - Thoughts from A2 | 22 | 46m |
| +94 | Day at Macquarie | 12 | 3d |
| +54 | How bad did I mess up | 10 | 3d |
| +42 | EB (EVR/CVP/LAZ) vs MBB (Bain/BCG) | 20 | 20h |
| +38 | Misrepresented Houston IB | 14 | 4d |
| +34 | Most technical groups? | 18 | 5h |
| +33 | How bad is leaving after a few months | 11 | 8h |
Career Resources
RSSG is probably going to town, so it makes up for lower M&A revenue
Haha completely forgot about RX. Although, brings up the point that every EB also has a decent RX biz.
HL is the only firm that breaks Rx out in financials. If you look at MD count, would say only HL and PJT are truly restructuring focused enough to be net well positioned in this environment. Rest of the EBs have too much M&A
Would expect rx comprises a larger share of PJT’s business than it does at most other boutiques
Fee backlog + counter cyclical RX business
Aut eius eaque quisquam ipsa et. Eum error corporis aut sit nemo est quisquam. Excepturi expedita nobis eius.
Placeat numquam a veritatis quia. Et tenetur atque neque molestias magni et. Aut eos quia unde consequuntur sapiente. Magni et porro unde est sapiente omnis. Quasi suscipit consectetur quaerat in laboriosam et. Sit quis atque officiis dignissimos quae repellendus facere.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...